The DTX3L antibody targets the Deltex3-like (DTX3L) protein, a member of the Deltex family of E3 ubiquitin ligases involved in ubiquitination-mediated protein degradation and signaling regulation. DTX3L is known to interact with PARP9 (BAL1) to form a complex that plays dual roles in immune responses and DNA repair. This complex is implicated in interferon-γ signaling, where it facilitates ubiquitination and degradation of specific substrates, modulating macrophage activation and antiviral defense. DTX3L-PARP9 also contributes to oncogenesis, particularly in lymphomas, by promoting cell survival and genomic instability.
Antibodies against DTX3L are essential tools for studying its expression, localization, and functional roles in these pathways. They are widely used in techniques like Western blotting, immunofluorescence, and co-immunoprecipitation to explore DTX3L's interaction networks and regulatory mechanisms. Research utilizing DTX3L antibodies has shed light on its involvement in inflammatory diseases, cancer progression, and host-pathogen interactions, making it a potential therapeutic target. The development and validation of these antibodies have advanced understanding of how ubiquitin ligase complexes fine-tune cellular responses to stress, infection, and malignant transformation.